Primary Biliary Cholangitis Pipeline Drugs Report 2025: Transformative Research, Competitive Landscape, and Future Treatment Prospects

The Primary Biliary Cholangitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of ...
Business Wire

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
Healio

Intercept pulls Ocaliva from US market; all clinical trials for PBC now on hold

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary cholangitis, following a series of costly FDA rulings that have whittled ...
Mena FN

Primary Biliary Cholangitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Zydus Therapeutics, Calliditas Therapeutics, Hepagene ...

"Primary Biliary Cholangitis Clinical Trials"DelveInsight's,“Primary Biliary Cholangitis (PBC)- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline ...
Business Wire

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...
Becker's ASC

FDA advisory committee to recommend approval of primary biliary cholangitis treatment drug: 4 takeaways

The FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously to recommend accelerated approval of Intercept Pharmaceuticals’ Ocaliva. 1. Ocaliva (obeticholic acid) is intended for the ...
Zacks Investment Research on MSN

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead Sciences, Inc. GILD, one of the top biotech companies, has put up a robust performance so far in 2025. Shares of the ...
Nasdaq

Ipsen's Iqirvo Secures FDA Accelerated Approval For Primary Biliary Cholangitis Treatment

(RTTNews) - The U.S. Food and Drug Administration has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis or PBC in combination with ...
Morningstar

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of ...
News Medical

Challenges in treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma ...
Nasdaq

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...